Journal
KIDNEY INTERNATIONAL
Volume 77, Issue 9, Pages 755-757Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/ki.2010.26
Keywords
-
Categories
Ask authors/readers for more resources
Biomarkers hold promise for personalizing renal cancer care by potentially identifying patients most likely to benefit from novel therapies. Porta and colleagues report that among subjects with advanced renal-cell carcinoma receiving sunitinib treatment, those with above-normal levels of the circulating biomarkers vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin displayed significantly lower progression-free survival times. This Commentary reviews the current status of these biomarkers with respect to methodological issues, specificity, and biological plausibility. Kidney International (2010) 77, 755-757. doi: 10.1038/ki.2010.26
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available